Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/09/2019 09/10/2019 09/11/2019 09/12/2019 09/13/2019 Date
78.97(c) 77.91(c) 78.48(c) 76.07(c) 76.43(c) Last
934 572 1 246 992 871 031 2 310 996 1 646 076 Volume
-0.34% -1.34% +0.73% -3.07% +0.47% Change
More quotes
Financials (USD)
Sales 2019 2 123 M
EBIT 2019 335 M
Net income 2019 367 M
Finance 2019 1 807 M
Yield 2019 -
Sales 2020 2 430 M
EBIT 2020 502 M
Net income 2020 461 M
Finance 2020 2 426 M
Yield 2020 -
P/E ratio 2019 45,8x
P/E ratio 2020 36,1x
EV / Sales2019 6,89x
EV / Sales2020 5,77x
Capitalization 16 438 M
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (77.9%); - royalties (12.5%); - income from research and... 
Sector
Biotechnology & Medical Research
Calendar
09/18 | 07:10amPresentation
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
09/09INCYTE : Novartis investigational lung cancer therapy capmatinib granted FDA Bre..
AQ
09/03INCYTE : Summary ToggleIncyte Launches #MyMPNChallenge to Inspire the Myeloproli..
PU
09/03INCYTE : Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MP..
BU
09/03INCYTE : Summary ToggleData from Incyte's Oncology Portfolio to be Featured at t..
PU
09/03INCYTE : Data from Incyte's Oncology Portfolio to be Featured at the 2019 ESMO C..
BU
08/26ELI LILLY AND : Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor ..
AQ
08/23INCYTE : Summary ToggleLilly Announces Top-Line Phase 3 Results for Oral JAK Inh..
PU
08/22INCYTE : Summary ToggleIncyte to Present at Upcoming Investor Conferences
PU
08/22INCYTE : to Present at Upcoming Investor Conferences
BU
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02:48aA Plan to Fight Hep C -- WSJ
DJ
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
08/29GLOBAL MARKETS LIVE : Dell, United Airlines, UBS, Apple…
08/28U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
RE
08/28US Judge Mostly Sets Aside Jury Ruling on Repatha Patents -Reuters
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 93,79  $
Last Close Price 76,43  $
Spread / Highest target 54,4%
Spread / Average Target 22,7%
Spread / Lowest Target -1,87%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Lothar H. Finke Head-Clinical Development & General Manager-Japan
Dashyant Dhanak Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION20.19%16 438
IQVIA HOLDINGS INC30.28%29 649
LONZA GROUP33.96%25 385
CELLTRION, INC.--.--%18 337
EXACT SCIENCES CORPORATION69.11%13 817
SEATTLE GENETICS, INC.24.66%11 927